BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Mallinckrodt
Fish and Richardson
Citi
Cerilliant
US Army
Johnson and Johnson
McKesson
Daiichi Sankyo
Express Scripts

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,759,328

« Back to Dashboard

Which drugs does patent 7,759,328 protect, and when does it expire?

Patent 7,759,328 protects SYMBICORT and is included in one NDA.

Protection for SYMBICORT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-nine patent family members in twenty-seven countries.
Summary for Patent: 7,759,328
Title:Composition for inhalation
Abstract:The invention relates to a formulation comprising formoterol and budesonide for use in the treatment of respiratory diseases. The composition further contains HFA 227, PVP and PEG, preferably PVP K25 and PEG 1000.
Inventor(s): Govind; Nayna (Leicestershire, GB), Marlow; Maria (Leicestershire, GB)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:10/502,685
Patent Claim Types:
see list of patent claims
Composition; Compound; Use;

Drugs Protected by US Patent 7,759,328

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca SYMBICORT budesonide; formoterol fumarate dihydrate AEROSOL, METERED;INHALATION 021929-001 Jul 21, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Astrazeneca SYMBICORT budesonide; formoterol fumarate dihydrate AEROSOL, METERED;INHALATION 021929-002 Jul 21, 2006 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,759,328

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden0200312Feb 01, 2002
Sweden0200312Feb 1, 2002
PCT Information
PCT FiledJanuary 29, 2003PCT Application Number:PCT/SE03/00156
PCT Publication Date:August 07, 2003PCT Publication Number: WO03/063842

Non-Orange Book US Patents Family Members for Patent 7,759,328

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,143,239 Composition for inhalation ➤ Subscribe
8,575,137 Composition for inhalation ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,759,328

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 423552 ➤ Subscribe
Austria 463241 ➤ Subscribe
Australia 2003206289 ➤ Subscribe
Brazil 0307193 ➤ Subscribe
Canada 2474479 ➤ Subscribe
China 1287774 ➤ Subscribe
China 1625392 ➤ Subscribe
Colombia 5611098 ➤ Subscribe
Cyprus 1109030 ➤ Subscribe
Cyprus 1110081 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Daiichi Sankyo
Boehringer Ingelheim
US Department of Justice
Covington
McKesson
Citi
UBS
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot